Health and Medicine News This Week: GLP-1 Cancer Findings, One-Shot Gene Editing, and 6 Breakthroughs You Should Know
It was a fast week in medicine. Weight-loss drugs picked up a striking new cancer signal, a single infusion rewrote the rules for cholesterol control, and researchers began to explain why the same blockbuster drugs work wonders for some people and barely move the needle for others. Here are the six developments worth your attention, plus a quick-hit roundup of everything else on the radar.
| Story | The headline number | Stage / source | Why it matters |
|---|---|---|---|
| GLP-1 drugs & breast cancer | ~30% lower odds | Observational; ASCO 2026 / JCO Oncology Practice | Hints at a prevention role beyond weight loss |
| VERVE-102 gene editing | Up to 62% LDL drop | Phase 1; NEJM (Heart-2 trial) | A potential one-and-done cholesterol fix |
| GLP-1 non-responders | Specific gene variants | Lab/genetic research | A step toward personalized obesity care |
| Strength training & longevity | Lower mortality risk | Population study | Muscle work, not just cardio, may extend life |
| Fried potatoes & diabetes | ~20% higher risk | ~205,000 people, ~40 years | Cooking method matters more than the potato |
| Myeloma immunotherapy | ~2 in 3 complete response | Newly approved therapy | New hope after relapse |
1. Weight-loss drugs picked up a surprising cancer signal
The week’s most talked-about finding came out of the American Society of Clinical Oncology (ASCO) annual meeting and was published the same day in JCO Oncology Practice. Researchers at the University of Pennsylvania looked back at health records for more than 110,000 women between the ages of 45 and 80 who were overweight or obese. Women who had been prescribed GLP-1 medications — the class behind Ozempic, Wegovy, Mounjaro, and Zepbound — were roughly 30% less likely to be diagnosed with breast cancer than women who had not taken the drugs.
Importantly, the protective signal held up even after the team matched users and non-users on age, race, ethnicity, body mass index, breast density, and diabetes status — which suggests the effect isn’t simply a byproduct of who happens to take these drugs. Researchers think several mechanisms could be at play, including reduced chronic inflammation, better insulin sensitivity, and the metabolic shifts that come with weight loss.
A few cautions are worth keeping front and center. This was an observational study, so it can show an association but cannot prove the drugs themselves prevent cancer. The absolute difference was modest — on the order of a few fewer cases per 1,000 women — and the analysis didn’t track which specific drug, dose, or duration people used. The lead researcher framed it as a reason to investigate these medicines as possible prevention tools, not as grounds to prescribe them for that purpose today. A prospective randomized trial is now in the works.
2. A single infusion that may rewrite cholesterol care
Imagine treating high cholesterol with a one-time treatment instead of a daily pill. That’s the promise behind early results for VERVE-102, an experimental gene-editing therapy reported in The New England Journal of Medicine from the Heart-2 trial. In the study, a single infusion lowered LDL — the “bad” cholesterol — by up to 62% in adults with an inherited form of very high cholesterol or premature coronary artery disease, with the effect lasting many months.
The therapy uses base editing to switch off PCSK9, a liver gene that normally limits how much LDL the body clears from the blood. People born with a naturally quiet version of that gene tend to have low cholesterol and lower heart-disease risk for life; the treatment aims to copy that natural advantage from a single dose. In the early-phase trial, the high dose cut PCSK9 levels by as much as 88%, and investigators reported no treatment-related serious adverse events — a meaningful result given the safety hurdles gene-editing programs have faced.
This is still a small, early study, and longer follow-up in larger groups is needed before anyone can call it a cure. But for the millions who struggle to stay on daily statins or injections, a durable, set-it-and-forget-it option would be a genuine shift in preventive cardiology. The therapy originated at Verve Therapeutics, which Eli Lilly acquired in 2025.
3. Why the same drug transforms one person and disappoints another
Anyone who has watched GLP-1 medicines work miracles for one friend and almost nothing for another has wondered why. This week, scientists offered part of the answer: they identified genetic variants that appear to make some people far less responsive to GLP-1 drugs used for type 2 diabetes and weight management.
The practical upshot is the direction of travel, not an immediate test at the pharmacy. If responsiveness is partly written into our genes, clinicians may eventually be able to predict who will benefit most — and steer everyone else toward a different therapy sooner, instead of months of trial and error. It’s a concrete step toward the long-promised era of personalized obesity and diabetes care.
4. A few sessions in the weight room may help you live longer
Cardio gets most of the longevity headlines, but resistance training had a strong week. A new analysis suggests that lifting weights even a couple of times a week is associated with a lower risk of dying over the study period — benefits that go beyond simply building visible muscle.
Muscle is metabolically active tissue: it helps regulate blood sugar, supports balance and bone strength, and protects against the frailty that drives so many problems later in life. The takeaway isn’t that cardio doesn’t matter — it’s that strength work deserves a real place in the weekly routine, not an afterthought.
5. The potato is probably fine. The fryer is the problem.
A large study that followed more than 205,000 people for nearly four decades found that eating French fries about three times a week was linked to a roughly 20% higher risk of type 2 diabetes. The same risk did not show up for boiled, baked, or mashed potatoes — a strong hint that the issue is the deep-frying and what comes with it, not the potato itself.
It’s a useful reminder that how a food is prepared can matter as much as the food on the plate. Swapping fries for a baked or boiled version — or for whole grains — is the kind of small, repeatable change that adds up over years.
6. An immunotherapy win for hard-to-treat blood cancer
For people with multiple myeloma that has relapsed after earlier treatment, options can run thin. This week brought encouraging news: a recently approved cancer immunotherapy was reported to push nearly two-thirds of patients with relapsed multiple myeloma into a complete response — meaning no detectable signs of the cancer by standard measures.
Complete response is not the same as a permanent cure, and these therapies carry real risks that require specialized care. But for a disease defined by relapse, getting that many heavily pretreated patients to a complete response is a meaningful advance and a reason for cautious optimism.
Also on the radar this week
A urine test for earlier autism detection
Researchers described a simple urine test that might help flag children likely to be diagnosed with autism earlier than today’s best assessment tools — potentially opening the door to earlier support. (Source: Drugs.com, June 3, 2026.)
Disposable vapes may get more toxic the longer they’re used
A new study suggests high-puff e-cigarettes can release more toxic compounds the more they are used — a concern as device capacities climb. (Source: Drugs.com, June 3, 2026.)
Scientists flag free-living amoebae as an underrated threat
Researchers warned that free-living amoebae may be a more serious public-health risk than appreciated, capable of causing deadly infections and shielding other dangerous microbes from water treatment. (Source: ScienceDaily, June 6, 2026.)
The supplements older adults actually need
A practical reminder that, for many older adults, the real question isn’t whether to take a shelf of supplements but whether they have a specific deficiency — with vitamins like B12 and D mattering most when levels are genuinely low. (Source: ScienceDaily, June 6, 2026.)
Sources & further reading
- ScienceDaily — Health & Medicine and Top Health News (June 5–7, 2026): sciencedaily.com/news/health_medicine
- ScienceDaily — “Ozempic and Similar Weight-loss Drugs Linked to 30% Lower Breast Cancer Risk”: link
- Healthline — “GLP-1 Drugs Lower Breast Cancer Risk by 30%” (June 3, 2026): link
- HealthDay / U.S. News & Drugs.com — GLP-1 and breast cancer coverage (June 3, 2026): link
- JCO Oncology Practice — McDonald ES et al. (June 2, 2026); presented at ASCO 2026.
- The New England Journal of Medicine — Heart-2 interim analysis of VERVE-102 (PCSK9 base editing).
- UCL News — “Promising gene editing therapy lowers ‘bad’ cholesterol”: link
- STAT News — Eli Lilly / Verve VERVE-102 trial data (May 25, 2026): link
- Drugs.com — Health, Medical & Pharma News (June 3, 2026): drugs.com/news
- Medscape — Today on Medscape (June 5, 2026): medscape.com
Disclaimer. This article is published by Vanderbiltreport.com for general informational and educational purposes only. It summarizes recently reported health and medicine research and is not medical advice. Findings described here are often early or observational and may change as further research is completed; references to specific drugs or therapies do not constitute endorsement, and many uses discussed are investigational and not approved for those purposes. Always consult a qualified healthcare professional before making any decision about your health, medications, or treatment. Vanderbiltreport.com makes no warranty as to the accuracy or completeness of third-party research summarized here and accepts no liability for actions taken based on this content. © 2026 Vanderbiltreport.com. All rights reserved.
